Hemmelrather Weg 201
Leverkusen 51377
Germany
https://www.biofrontera.com
Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 91
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Ms. Pilar de la Huerta Martinez | CFO & Member of Executive Board | 290,64k | N/A | 1969 |
Mr. Ludwig M. Lutter | Member of the Executive Board | 435,65k | N/A | 1967 |
Mr. Alexander Richardson | Head of UK Sales Team | N/A | N/A | N/A |
Dr. Matthias Naumann | Head of Sales & Marketing - Europe | N/A | N/A | N/A |
Dr. Montserrat Foguet Ph.D. | Managing Director of Biofrontera UK Ltd. | N/A | N/A | N/A |
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; and Belixos, a medical skin care series for irritated and sensitive skin. It has a collaboration and partnership agreement with Maruho Co., Ltd. The company was founded in 1997 and is headquartered in Leverkusen, Germany.
Biofrontera AGs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.